Clinical analysis, drug designing and QSAR studies on rheumatoid arthritis

International Journal of Pharma and Bio Sciences

Volumn 1, Issue 4, 2010, Pages

  Kaladhar, D S V G K ^a   Satyanarayana, K V V V ^a   Krishna Chaitanya, A ^a   Zakir Hussain, S A K ^a  

^a GITAM UNIVERSITY   (India)

Author keywords

QSAR; Rheumatoid arthritis

Indexed keywords

ACETYLSALICYLIC ACID; AURANOFIN; COLCHICINE; CORTISONE ACETATE; CYCLOSPORIN; CYSTINE; DEOXYCORTICOSTERONE PIVALATE; DICLOFENAC; DIFLUNISAL; FENOPROFEN; HISTIDINE; HYDROCORTISONE; IBUPROFEN; INDOMETACIN; KETOPROFEN; LEFLUNOMIDE; MECLOFENAMIC ACID; MEFENAMIC ACID; NAPROXEN; NIFLUMIC ACID; PENICILLAMINE; PHENACETIN; PHENYLBUTAZONE; PIROXICAM; SALAZOSULFAPYRIDINE; SULFINPYRAZONE; SULINDAC; TEMSIROLIMUS; TENOXICAM; UNINDEXED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG DESIGN; DRUG DETERMINATION; EOSINOPHIL COUNT; FEMALE; HUMAN; LIGAND BINDING; LYMPHOCYTE COUNT; MALE; MOLECULAR DOCKING; MONOCYTE; NEUTROPHIL COUNT; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RHEUMATOID ARTHRITIS; SEX DIFFERENCE;

EID: 84455202789     PISSN: None     EISSN: 09756299     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. http://arthritis.about.com/cs/mtx/a/mtx.htm
2. Edwards J, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close D, Stevens R and Shaw T. Efficacy of B-celltargeted therapy with rituximab in patients with Rheumatoid arthritis. N Engl J Med, 350 (25): 2572-2581, (2004).
3. Mersich C and Jungbauer A, Generation of bioactive peptides by biological libraries. J. Chromatogr. B, 861: 160-170, (2008).
4. Valencia C.A, Cotten S.W, Dong B and Liu R, mRNA-display-based selections for proteins with desired functions: a protease-substrate case study. Biotechnol. Prog, 24: 561-569, (2008).
5. Kitamura K, Yoshida C, Kinoshita C, Kadowaki T, Takahashi Y, Tayama T, Kawakubo T, Naimuddin M, Salimullah Md, Nemoto N, Hanada K, Husimi Y, Yamamoto K and Nishigaki K, Development of systemic in vitro evolution and its application to generation of peptide aptamer-based inhibitors of cathepsin. E. J. Mol. Biol, 387: 1186-1198, (2009).
6. Warren G.L, Andrews C.W, Capelli A.M, Clarke B, LaLonde J, Lambert M.H, Lindvall M, Nevins N, Semus S.F, Senger S, Tedesco G, Wall I.D, Woolven J.M, Peishoff C.E and Head M.S, A critical assessment of docking programs and scoring functions. J. Med. Chem, 49: 5912-5931, (2006).
7. Hetenyi C and van der Spoel D, Efficient docking of peptides to proteins without prior knowledge of the binding site. Protein Sci, 11: 1729-1737, (2002).
8. Hetenyi C, van der Spoel D, Blind docking of drug-sized compounds to proteins with up to a thousand residues. FEBS Lett, 580: 1447-1450, (2006).
9. Wang J, Kollman P.A and Kuntz I.D, Flexible ligand docking: a multistep strategy approach. Proteins, 36: 1-19, (1999).
10. Arun Prasad P and Gautham N, A new peptide docking strategy using a mean field technique with mutually orthogonal Latin square sampling. J. Comput. Aided Mol. Des, 22: 815-829, (2008).
11. Shoichet B.K and Kuntz I.D, Matching chemistry and shape in molecular docking. Protein Eng, 6: 723-732, (1993).
12. Morris G.M, Goodsell D.S, Huey R and Olson A.J, Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4. J. Comput. Aided Mol. Des, 10: 293-304, (1996).